Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The Omni Legend 32 PET/CT system features silicon photomultiplier (SiPM)-based detectors with bismuth germanium oxide crystals and a 32-cm axial field of view (FOV). The present study aimed to determine the performance characteristics of the Omni Legend 32 PET/CT system according to National Electrical Manufacturers Association (NEMA) NU 2-2018 standards. The PET component of this system comprises 22 detector modules; each module contains 24 detector blocks with 72 bismuth germanium oxide crystals with a volume of 4.1 × 4.1 × 30 mm coupled to 18 SiPM devices with a 6 × 6 mm area, resulting in an axial FOV of 32 cm. The spatial resolution, sensitivity, count rate performance, and image quality delivered by PET were evaluated using the NEMA NU 2-2018 standard. PET images of 2 patients were evaluated to get a visual first impression of the Omni Legend 32 PET/CT system together with Precision DL. The average spatial resolution at 1, 10, and 20 cm from the central axis was 4.3, 5.3, and 6.2 mm, respectively, for filtered backprojection and 3.7, 4.3, and 5.1 mm, respectively, for ordered-subset expectation maximization. The NEMA sensitivity was 47.30 and 47.05 cps/kBq at the axial center of the FOV and at a 10-cm radial offset, respectively. The scatter fraction, count rate accuracy, and peak noise-equivalent count rates were 35.4%, 1.7%, and 501.7 kcps, respectively, at 15.7 kBq/mL. Contrast recovery for the NEMA body phantom from the smallest to the largest sphere ranged from 61.3% to 93.0%, with a background variability of 5.4%-11.7% and a lung error of 5.1% for Q.Clear (β-value, 50). Good patient image quality was obtained with the Omni Legend 32. The Omni Legend 32 has class-leading sensitivity and count rates within the category of whole-body PET systems while maintaining spatial resolution broadly comparable to that of other current SiPM-based PET/CT systems. This combination of properties results in a very good image quality.

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.123.266140DOI Listing

Publication Analysis

Top Keywords

omni legend
24
pet/ct system
16
bismuth germanium
12
germanium oxide
12
nema 2-2018
12
legend pet/ct
12
spatial resolution
12
image quality
12
performance characteristics
8
2-2018 standards
8

Similar Publications

The Omni Legend (GE Healthcare), equipped with a digital bismuth germanium oxide PET/CT system, has been recently developed. However, the performance of the Omni Legend without a time-of-flight (TOF) system for F-fluciclovine imaging is still unclear. Therefore, this study evaluated the image quality of the Omni Legend according to the Japanese brain tumor phantom test (JBT) criteria, and assessed its potential use for F-fluciclovine imaging.

View Article and Find Full Text PDF

Background: The digital-BGO PET/CT system, Omni Legend 32, incorporates modified block sequential regularized expectation maximization (BSREM) image reconstruction and a deep learning-based time-of-flight (TOF)-like image quality enhancement process called Precision DL (PDL). The present study aimed to define the fundamental characteristics of PDL using phantom and clinical images.

Methods: A NEMA IEC body phantom was scanned using the Omni Legend 32 PET/CT system.

View Article and Find Full Text PDF

Purpose: To assess the lower [F]FDG limit in administered activity and/or scan time reduction capabilities of a digital-BGO 32-cm axial field-of-view PET system while being compliant with current and updated EANM Research Ltd Fluorine-18 accreditation specifications (EARL and EARL).

Methods: EARL and EARL compliance of the digital-BGO system (Omni Legend 32 cm) was tested for several reconstructions, including those that apply precision deep learning-based image enhancement (PDL) as postprocessing, using the calibration QC and NEMA IEC phantom measurements. The image quality QC scan was repeated every hour for 7 h, with each subsequent hour representing a lower administered activity, and reconstructed for various times per bed position, i.

View Article and Find Full Text PDF

Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown.

Methods: We collected clinical, pathologic, and demographic variables from five institutions for patients whose tumors met criteria for SMARCA4-UTs (undifferentiated phenotype and loss of SMARCA4 (BRG1) by immunohistochemistry).

Results: We identified 92 patients with SMARCA4-UTs; 58 (63%) had stage IV disease at diagnosis and 16 (17%) developed recurrent or metastatic disease after initial diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • Approximately 10% of lung adenocarcinomas (LUAD) have mucinous histology (LUADMuc), which is linked to a lighter/absent smoking history and a higher prevalence of KRAS mutations compared to LUAD without this histology (LUADnon-muc).
  • A study analyzed features and treatment outcomes of LUADMuc and LUADnon-muc patients, revealing LUADMuc patients had less aggressive disease characteristics and a poorer response to current therapies, especially immunotherapy.
  • Overall, LUADMuc showed lower objective response rates, shorter progression-free and overall survival compared to LUADnon-muc, highlighting a need for more effective treatment strategies for this subgroup.
View Article and Find Full Text PDF